The Role of the Gut Microbiome in Multiple Sclerosis Risk and Progression: Towards Characterization of the “MS Microbiome”

Neurotherapeutics

Volumn 15, Issue 1, 2018, Pages 126-134

  Pröbstel, Anne Katrin ^a   Baranzini, Sergio E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

B cells; consortia; dysbiosis; genetics; Gut microbiome; multiple sclerosis; progression

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CD20 ANTIGEN; GLATIRAMER; IMMUNOGLOBULIN A ANTIBODY; NATALIZUMAB; PREDNISOLONE; RNA 16S;

B LYMPHOCYTE; DISEASE ACTIVITY; DISEASE EXACERBATION; DNA SEQUENCE; DYSBIOSIS; HUMAN; INTESTINE FLORA; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ANIMAL; GENETICS; IMMUNOLOGY; MICROBIOLOGY;

ANIMALS; B-LYMPHOCYTES; DISEASE PROGRESSION; DYSBIOSIS; GASTROINTESTINAL MICROBIOME; HUMANS; MULTIPLE SCLEROSIS; RISK FACTORS;

EID: 85034239164     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-017-0587-y     Document Type: Review

References (75)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372(9648): 1502-1517.
2. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007; 8(9): 913-919.
3. Rothhammer V, Quintana FJ. Role of astrocytes and microglia in central nervous system inflammation. Introduction. Semin Immunopathol 2015; 37(6): 575-576.
4. Krumbholz M, Derfuss T, Hohlfeld R, et al. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol 2012; 8(11): 613-623.
5. Prinz M, Priller J. The role of peripheral immune cells in the CNS in steady state and disease. Nat Neurosci 2017; 20(2): 136-144.
6. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356(6364): 63-66.
7. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355(11): 1124-1140.
8. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017; 376(3): 221-234.
9. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376(3): 209-220.
10. Campbell RD, Trowsdale J. Map of the human MHC. Immunol Today 1993; 14(7): 349-352.
11. Patsopoulos N, Baranzini SE, Santaniello A, et al. The Multiple Sclerosis Genomic Map: role of peripheral immune cells and resident microglia in susceptibility. Available at: https://www.biorxiv.org/content/early/2017/07/13/143933. Accessed November 6, 2017.
12. Hedstrom AK, Alfredsson L, Olsson T. Environmental factors and their interactions with risk genotypes in MS susceptibility. Curr Opin Neurol 2016; 29(3): 293-298.
13. Hedstrom AK, Olsson T, Alfredsson L. Smoking is a major preventable risk factor for multiple sclerosis. Mult Scler 2016; 22(8): 1021-1026.
14. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol 2017; 13(1): 25-36.
15. Rhead B, Baarnhielm M, Gianfrancesco M, et al. Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk. Neurol Genet 2016; 2(5): e97.
16. Sundqvist E, Bergstrom T, Daialhosein H, et al. Cytomegalovirus seropositivity is negatively associated with multiple sclerosis. Mult Scler 2014; 20(2): 165-173.
17. Nealson KH, Venter JC. Metagenomics and the global ocean survey: what's in it for us, and why should we care? Isme J 2007; 1(3): 185-187.
18. Rajagopala SV, Vashee S, Oldfield LM, et al. The human microbiome and cancer. Cancer Prev Res 2017; 10(4): 226-234.
19. Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature 2007; 449(7164): 804-810.
20. Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature 2016; 535(7610): 75-84.
21. Berer K, Mues M, Koutrolos M, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011; 479(7374): 538-541.
22. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9(5): 313-323.
23. Ivanov, II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139(3): 485-498.
24. Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013; 500(7461): 232-236.
25. Grice EA, Segre JA. The human microbiome: our second genome. Annu Rev Genomics Hum Genet 2012; 13: 151-170.
26. Sandoval-Motta S, Aldana M, Martinez-Romero E, et al. The human microbiome and the missing heritability problem. Front Genet 2017; 8: 80.
27. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005; 366(9497): 1653-1666.
28. Cree BA, Spencer CM, Varrin-Doyer M, et al. Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens. Ann Neurol 2016; 80(3): 443-447.
29. Gacias M, Gaspari S, Santos PM, et al. Microbiota-driven transcriptional changes in prefrontal cortex override genetic differences in social behavior. Elife 2016; 5.
30. Forsythe P, Kunze WA. Voices from within: gut microbes and the CNS. Cell Mol Life Sci 2013; 70(1): 55-69.
31. Buscarinu MC, Cerasoli B, Annibali V, et al. Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: a pilot study. Mult Scler 2017; 23(3): 442-446.
32. Hauser SL. The Charcot Lecture | beating MS: a story of B cells, with twists and turns. Mult Scler 2015; 21(1): 8-21.
33. Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014; 507(7492): 366-370.
34. Colpitts SL, Kasper LH. Influence of the gut microbiome on autoimmunity in the central nervous system. J Immunol 2017; 198(2): 596-604.
35. Kim M, Kim CH. Regulation of humoral immunity by gut microbial products. Gut Microbes 2017: 1-8.
36. Wesemann DR, Portuguese AJ, Meyers RM, et al. Microbial colonization influences early B-lineage development in the gut lamina propria. Nature 2013; 501(7465): 112-115.
37. Rosser EC, Oleinika K, Tonon S, et al. Regulatory B cells are induced by gut microbiota-driven interleukin-1beta and interleukin-6 production. Nat Med 2014; 20(11): 1334-1339.
38. Kubinak JL, Round JL. Do antibodies select a healthy microbiota? Nat Rev Immunol 2016; 16(12): 767-774.
39. Palm NW, de Zoete MR, Cullen TW, et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 2014; 158(5): 1000-1010.
40. Kau AL, Planer JD, Liu J, et al. Functional characterization of IgA-targeted bacterial taxa from undernourished Malawian children that produce diet-dependent enteropathy. Sci Transl Med 2015; 7(276): 276ra224.
41. Viladomiu M, Kivolowitz C, Abdulhamid A, et al. IgA-coated E. coli enriched in Crohn's disease spondyloarthritis promote Th17-dependent inflammation. Sci Transl Med 2017; 9(376).
42. Okai S, Usui F, Yokota S, et al. High-affinity monoclonal IgA regulates gut microbiota and prevents colitis in mice. Nat Microbiol 2016; 1(9): 16103.
43. Hughes LE, Smith PA, Bonell S, et al. Cross-reactivity between related sequences found in Acinetobacter sp., Pseudomonas aeruginosa, myelin basic protein and myelin oligodendrocyte glycoprotein in multiple sclerosis. J Neuroimmunol 2003; 144(1-2): 105-115.
44. Cekanaviciute E, Yoo BB, Runia TF, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A 2017;114:10713-10718.
45. Rumah KR, Linden J, Fischetti VA, et al. Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease. PLOS ONE 2013; 8(10): e76359.
46. Le Berre L, Rousse J, Gourraud PA, et al. Decrease of blood anti-alpha1,3 Galactose Abs levels in multiple sclerosis (MS) and clinically isolated syndrome (CIS) patients. Clin Immunol 2017; 180: 128-135.
47. Galili U. Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits. Immunology 2013; 140(1): 1-11.
48. Jangi S, Gandhi R, Cox LM, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun 2016; 7: 12015.
49. Tremlett H, Fadrosh DW, Faruqi AA, et al. Gut microbiota composition and relapse risk in pediatric MS: a pilot study. J Neurol Sci 2016; 363: 153-157.
50. Chen J, Chia N, Kalari KR, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep 2016; 6: 28484.
51. Miyake S, Kim S, Suda W, et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to Clostridia XIVa and IV clusters. PLOS ONE 2015; 10(9): e0137429.
52. Cantarel BL, Waubant E, Chehoud C, et al. Gut microbiota in multiple sclerosis: possible influence of immunomodulators. J Investig Med 2015; 63(5): 729-734.
53. Berer K, Gerdes LA, Cekanaviciute E, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A 2017;114:10719-10724.
54. Greenhill C. Gut microbiota: Anti-cancer therapies affected by gut microbiota. Nat Rev Gastroenterol Hepatol 2014; 11(1): 1.
55. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015; 528(7581): 262-266.
56. Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342(6161): 967-970.
57. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342(6161): 971-976.
58. Marotz C, Amir A, Humphrey G, et al. DNA extraction for streamlined metagenomics of diverse environmental samples. Biotechniques 2017; 62(6): 290-293.
59. Kuczynski J, Lauber CL, Walters WA, et al. Experimental and analytical tools for studying the human microbiome. Nat Rev Genet 2011; 13(1): 47-58.
60. Turnbaugh PJ, Ridaura VK, Faith JJ, et al. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009; 1(6): 6ra14.
61. Derrien M, Vaughan EE, Plugge CM, et al. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 2004; 54(Pt 5): 1469-1476.
62. Derrien M, Van Baarlen P, Hooiveld G, et al. Modulation of mucosal immune response, tolerance, and proliferation in mice colonized by the mucin-degrader Akkermansia muciniphila. Front Microbiol 2011; 2: 166.
63. Ganesh BP, Klopfleisch R, Loh G, et al. Commensal Akkermansia muciniphila exacerbates gut inflammation in Salmonella Typhimurium-infected gnotobiotic mice. PLOS ONE 2013; 8(9): e74963.
64. Nayfach S, Rodriguez-Mueller B, Garud N, et al. An integrated metagenomics pipeline for strain profiling reveals novel patterns of bacterial transmission and biogeography. Genome Res 2016; 26(11): 1612-1625.
65. Gerritsen J, Smidt H, Rijkers GT, et al. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr 2011; 6(3): 209-240.
66. Wekerle H. Brain autoimmunity and intestinal microbiota: 100 trillion game changers. Trends Immunol 2017; 38(7): 483-497.
67. Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 2016; 167(6): 1469-1480.
68. Goodman AL, Kallstrom G, Faith JJ, et al. Extensive personal human gut microbiota culture collections characterized and manipulated in gnotobiotic mice. Proc Natl Acad Sci U S A 2011; 108(15): 6252-6257.
69. McNulty NP, Yatsunenko T, Hsiao A, et al. The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci Transl Med 2011; 3(106): 106ra106.
70. Faith JJ, McNulty NP, Rey FE, et al. Predicting a human gut microbiota's response to diet in gnotobiotic mice. Science 2011; 333(6038): 101-104.
71. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009; 457(7228): 480-484.
72. Smith MI, Yatsunenko T, Manary MJ, et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science 2013; 339(6119): 548-554.
73. Reikvam DH, Erofeev A, Sandvik A, et al. Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression. PLOS ONE 2011; 6(3): e17996.
74. Ringeisen BR, Rincon K, Fitzgerald LA, et al. Printing soil: a single-step, high-throughput method to isolate micro-organisms and near-neighbour microbial consortia from a complex environmental sample. Methods Ecol Evol 2015; 6(2): 209-217.
75. (IMSGC) IMSGC, Hafler DA, Compston A, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357(9): 851-862.